Rifampicin and long‐acting cabotegravir‐rilpivirine: Therapeutic drug monitoring‐guided management of a major drug–drug interaction—A case report
British Journal of Clinical Pharmacology · 2026-11-15
DOI: 10.1002/bcp.70933 ↗At a glance
Fallbericht in British Journal of Clinical Pharmacology, published online on 2026-11-15. Written by Lorenzo Ciullini and 3 co-authors. Institution: Infection Control Programme and World Health Organization Collaborating Centre on Infection Prevention and Control and Antimicrobial Resistance, Gene…. 20 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Long‐acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) is subject to clinically significant drug–drug interactions with strong enzyme inducers such as rifampicin due to markedly reduced drug exposure and potential development of resistance. However, real‐world evidence on managing this interaction remains scarce. We report a person with HIV, virologically suppressed on LAI CAB/RPV, who developed an orthopaedic implant‐associated infection requiring 10‐week rifampicin‐containing therapy for its antibiofilm activity. Further LAI CAB/RPV injections were withheld, and oral tenofovir disoproxil fumarate/emtricitabine once daily plus dolutegravir 50 mg twice daily was initiated. This regimen was continued until 3 weeks after rifampicin discontinuation; afterwards, dolutegravir was reduced to once daily. LAI CAB/RPV was restarted 5 weeks after rifampicin withdrawal; oral antiretroviral therapy was discontinued. Serial therapeutic drug monitoring (TDM) showed a rapid decline in plasma CAB and RPV concentrations from day 8 after rifampicin initiation, with both drugs falling below the efficacy thresholds by day 10. In contrast, tenofovir and dolutegravir concentrations remained within the therapeutic range during rifampicin co‐administration, whereas twice‐daily dolutegravir concentrations exceeded the therapeutic range 3 weeks after rifampicin discontinuation. HIV RNA remained undetectable throughout follow‐up. This case confirms the clinically relevant interaction between rifampicin and LAI CAB/RPV, as illustrated by the rapid decline in residual CAB and RPV plasma concentrations following rifampicin initiation. Temporary substitution with a recommended first‐line oral antiretroviral regimen maintained adequate drug exposure, was well tolerated and preserved virological suppression throughout rifampicin treatment. TDM allowed to characterize the interaction and may support individualized management in selected complex clinical situations.
Subjects
Author keywords
Authors and institutions
- Infection Control Programme and World Health Organization Collaborating Centre on Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
- HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Division of Infectious Diseases, Basel University Hospital and University of Basel, Basel, Switzerland.
- Centre for Experimental Therapeutics, University of Liverpool, Liverpool, UK.
ORCID profiles: Lorenzo Ciullini, Paul Thoueille, Catia Marzolini
Cite
APA
Ciullini, L., Thoueille, P., Marzolini, C., & Marinosci, A. (2026). Rifampicin and long‐acting cabotegravir‐rilpivirine: Therapeutic drug monitoring‐guided management of a major drug–drug interaction—A case report. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70933
Vancouver
Ciullini L, Thoueille P, Marzolini C, Marinosci A. Rifampicin and long‐acting cabotegravir‐rilpivirine: Therapeutic drug monitoring‐guided management of a major drug–drug interaction—A case report. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70933
BibTeX
@article{Ciullini2026,
author = {Ciullini, Lorenzo and Thoueille, Paul and Marzolini, Catia and Marinosci, Annalisa},
title = {Rifampicin and long‐acting cabotegravir‐rilpivirine: Therapeutic drug monitoring‐guided management of a major drug–drug interaction—A case report},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70933}
}
EUVIMED